Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is set to launch a clinical study titled ‘Zavicefta Combination for Intravenous Infusion Special Investigation’ in Japan, focusing on patients with sepsis or renal impairment. The study aims to evaluate the safety and effectiveness of Zavicefta, a combination of Avibactam sodium and Ceftazidime hydrate, under real-world clinical conditions. This research is significant as it targets serious health conditions like sepsis and kidney function loss, which require effective treatment options.
The intervention being tested is Zavicefta, a drug combination designed to combat severe infections and renal impairment. It is administered intravenously, with the recommended dosage being 2.5 g three times daily.
The study is observational, employing a cohort model with a prospective time perspective. This design allows for the collection of data on the drug’s performance in a real-world setting without intervention allocation or masking.
The study is scheduled to start on September 15, 2025, with primary completion expected shortly thereafter. The last update was submitted on August 8, 2025, indicating that preparations are underway for the recruitment phase.
For investors, this study could influence Pfizer’s stock performance, especially if Zavicefta proves effective, potentially boosting market confidence. The study’s outcome may also impact competitors in the pharmaceutical industry focusing on similar treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.